Overview
Post-myocarditic cardiomyopathy refers to heart muscle dysfunction that develops following an episode of myocarditis, often leading to chronic heart failure and impaired cardiac function 1.Diagnosis
Clinical history of preceding myocarditis 1.
Echocardiography to assess left ventricular function and morphology 1.
Cardiac MRI for detailed assessment of myocardial inflammation and fibrosis 1.
Electrocardiogram (ECG) for signs of arrhythmias or conduction abnormalities 1.
Blood biomarkers such as troponin and B-type natriuretic peptide (BNP) for evaluation 1.Management
First-line treatments:
- Immunosuppressive therapy (e.g., corticosteroids, intravenous immunoglobulin) for acute cases 1.
- Diuretics (e.g., furosemide) for managing fluid overload 1.
Adjunctive treatments:
- Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for heart failure management 1.
- Beta-blockers to improve survival and reduce heart failure symptoms 1.
- Aldosterone antagonists (e.g., spironolactone) in severe cases 1.Special Populations
Pediatrics: Limited specific data; management generally follows adult guidelines with close monitoring 1.
Pregnancy: No specific data provided in the abstracts; individualized care with multidisciplinary approach recommended 1.
Elderly: Tailored treatment focusing on minimizing side effects and optimizing heart failure management 1.
Comorbidities: Consideration of additional cardiac and non-cardiac comorbidities in treatment planning 1.Key Recommendations
Utilize echocardiography and cardiac MRI for comprehensive diagnosis of post-myocarditic cardiomyopathy 1.
Implement immunosuppressive therapy early in the course of acute myocarditis to prevent progression to cardiomyopathy 1 (Evidence: Moderate).
Incorporate ACE inhibitors or ARBs in the management of chronic heart failure post-myocarditis to improve outcomes 1 (Evidence: Moderate).
Tailor treatment plans in special populations like pediatric patients and the elderly, emphasizing close monitoring and individualized care 1 (Evidence: Expert opinion).References
1 Dobay P, Sabidó M. Evaluating Data Quality by Proxy: Can We Evaluate All Dimensions of the European Medicines Agency Data Quality Framework for Registry-Based Post-Authorization Safety Studies?. Pharmacoepidemiology and drug safety 2026. link
2 El Rassi E, de Alarcon A, Lam D. Practice patterns in the management of post-tonsillectomy hemorrhage: An American Society of Pediatric Otolaryngology survey. International journal of pediatric otorhinolaryngology 2017. link
3 Inoue S, Masuyama H, Hiramatsu Y. Efficacy of transarterial embolisation in the management of post-partum haemorrhage and its impact on subsequent pregnancies. The Australian & New Zealand journal of obstetrics & gynaecology 2014. link
4 Hofman R, Zeebregts CJ, Dikkers FG. Fulminant post-tonsillectomy haemorrhage caused by aberrant course of the external carotid artery. The Journal of laryngology and otology 2005. link